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Abstract
Epstein–Barr virus nuclear antigen 1 (EBNA1) has a central role in the maintenance and segregation of the Epstein–Barr virus (EBV)
episome and by virtue of a glycine–alanine repeat domain is prevented from being endogenously processed for recognition by HLA class
I restricted cytotoxic T lymphocytes (CTLs). We found that EBNA1 expression resulted in growth inhibition and a G2/M arrest in human
squamous epithelial cell lines (SCC12F, SVK) but not epithelial cell lines of glandular origin (Hela, Ad/AH). The cytotoxicity of EBNA1
was associated with EBNA1 degradation and both these effects were blocked in SCC12F cells expressing either the anti-apoptotic bcl-2
protein or the EBV homolog of bcl-2, BHRF1. The endogenous degradation of EBNA1 in SVK epithelial cells was associated with specific
CTL recognition, an effect not evident in EBNA1-expressing Hela cells. Consistent with the inability of SVK cells to tolerate EBNA1
expression, studies with a recombinant EBV demonstrated that SVK cells are unable to maintain stable virus infection, whereas Hela cells
are able to efficiently establish latent EBV infection. These data have important implications for both the cellular requirements necessary
to sustain a stable EBV infection and for the possible role of CTL responses in controlling EBV infection of epithelial cells.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Epstein–Barr virus (EBV), a ubiquitous human herpes-
virus, is associated with the development of tumours of B
cell origin and of epithelial cell origin (Rickinson and Kieff,
2001). An in vitro corollary of the oncogenic capacity of
EBV is its ability to transform resting B cells into perma-
nently growing lymphoblastoid cell lines in which every
cell carries multiple episomal copies of the virus genome
and expresses a limited set of virus-encoded latent nuclear
(EBNA) and membrane (LMP) proteins (Rickinson and
Kieff, 2001; Murray and Young, 2002). Although only a
subset of these virus latent proteins are expressed in EBV-
associated tumors, expression of the EBNA1 nuclear pro-
tein is a common feature of all forms of EBV infection
consistent with the central role of this protein in the segre-
gation and maintenance of the episomal EBV genome
(Rickinson et al., 1996; Imai et al., 1998). EBNA1 is a DNA
binding phosphoprotein that through binding to the plasmid
origin of viral replication, oriP, is responsible for tethering
the virus episome to chromosomes during mitosis (Mare-
chal et al., 1999; Yates et al., 1996). Recent work provides
genetic evidence in support of the essential role of EBNA1
in the establishment of stable latent infection in proliferating
cells (Lee et al., 1999). Furthermore, EBNA1 can act as a
transcriptional transactivator and has been shown to up-
regulate the Cp and LMP1 promoters (Schlager et al., 1996;
Rickinson and Kieff, 2001).
The EBNA1 protein is separated into amino- and car-
boxyterminal domains by a glycine–glycine–alanine (GA)
repeat sequence that varies in size in different EBV isolates.
This GA repeat domain is a cis-acting inhibitor of MHC
class I-restricted presentation and appears to function by
inhibiting antigen processing via the ubiquitin/proteosome
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pathway (Levitskaya et al., 1995; Levitskaya et al., 1997).
This effect is also likely to be responsible for the long
half-life of the EBNA1 protein (Levitskaya et al., 1997).
Recent studies, however, demonstrate that exogenous pro-
cessing of EBNA1 results in presentation via the HLA class
I pathway to CD8 T cells and that EBNA1 is a major target
of HLA class II-restricted responses in healthy EBV-in-
fected adults (Blake et al., 1997; Munz et al., 2000). Di-
recting EBNA1 expression to B cells in transgenic mice
results in B cell lymphomas suggesting that EBNA1 may
have a direct role in oncogenesis, although the mechanisms
responsible for this effect and its relevance to the pathogen-
esis of EBV-associated tumours remain unknown (Wilson
et al., 1996). Although expression of EBNA1 has been
directly demonstrated in both EBV-positive nasopharyngeal
carcinoma (NPC) and gastric adenocarcinomas, the contri-
bution of EBNA1 expression to the carcinogenic process
has been assumed to relate to the role of the protein in
maintaining the extrachromosomal integrity of the EBV
episome (Imai et al., 1994; Murray et al., 1996). Challeng-
ing this view is work demonstrating that EBNA1 can en-
hance the tumorigenicity of EBV-negative NPC cells (Sheu
et al., 1996). Our previous work on EBV infection of SV40-
transformed keratinocytes (SVK) expressing the CR2 recep-
tor indicated that stable infection could only be achieved by
cloning out rare EBNA1-positive epithelial cells that were
subsequently found to be unable to differentiate (Knox et
al., 1996). This data suggested that the stable maintenance
of EBV in epithelial cells requires an undifferentiated en-
vironment and, consequently, that EBNA1 expression and
function may be influenced by the nature of the epithelial
cell background. During studies aimed at introducing indi-
vidual EBV latent genes into epithelial cells we found it
difficult to achieve stable expression of EBNA1 in cell lines
of squamous origin. This observation forms the basis of the
current study which demonstrates that EBNA1 expression is
toxic in certain epithelial cell environments and that this
effect involves EBNA1 degradation, cell growth inhibition,
apoptosis induction, and processing of EBNA1 for HLA
class I presentation. This previously unrecognised property
of EBNA1 has important consequences for our understand-
ing of immune responses to EBV-infected epithelial cells
and of the requirements for stable maintenance of latent
EBV infection in epithelium that are likely to play a central
role in the pathogenesis of virus-associated carcinomas.
Results
EBNA1 is toxic in SCC12F cells but not HeLa cells
In initial studies attempts were made to generate epithe-
lial cell lines stably expressing EBNA1 using electropora-
tion with either an EBNA1-expressing neomycin-resistant
plasmid [pZIPSV(X)1-neo-EBNA1] or a plasmid [pZ-
IPSV(X)1-neo] carrying the neomycin resistance gene
alone. The target epithelial cells were either the SCC12F
cell line or the HeLa cell line and neomycin selection was
performed over a 4-week period. Figure 1 demonstrates
that, whereas EBNA1-positive colonies could be selected in
HeLa cells at a similar efficiency to those carrying neomy-
cin resistance alone, no outgrowth of EBNA1-positive col-
onies was observed in the SCC12F background despite
efficient selection of cells transfected with the neomycin
resistance plasmid. This effect was not due to differences in
the ability of SCC12F cells to express neo resistance as
other work using similar vectors to deliver other transgenes
(e.g., EBNA2, Bcl-2) resulted in efficient selection of stably
expressing clones. This suggested that EBNA1 may confer
toxicity in SCC12F cells but not HeLa cells. However, it
was also observed that the EBNA1-positive HeLa cell col-
onies were significantly smaller than their neomycin-resis-
tant controls (Fig. 1A) and this growth disadvantage was
evident in the growth kinetics of isolated EBNA1-positive
clones selected for further analysis (data not shown). The
pooled data from 3 dishes is presented in Fig. 1B and similar
results were obtained in five independent experiments con-
firming the consistent, highly toxic effect of EBNA1 in
SCC12F cells compared to HeLa cells. The expression of
EBNA1 was confirmed in a number of selected HeLa clones
by immunostaining and immunoblotting (data not shown
and Fig. 6).
Adenovirus-mediated delivery of EBNA1 induces growth
arrest in certain epithelial cell lines
The inability to select for stable EBNA1 expression in
the SCC12F squamous carcinoma cell line led us to inves-
tigate the use of a recombinant adenovirus (RAd) for the
efficient delivery of EBNA1 to different epithelial cell lines.
A replication-defective (E1-deleted) recombinant adenovi-
rus (RAdEBNA1) was constructed that expressed EBNA1
from the CMV IE promoter. Infection of either HeLa cells
or a SV40-transformed squamous epithelial cell line, SVK,
with a multiplicity of infection (m.o.i.) of 100 m.o.i. of
RAdEBNA1 for 48–96 h resulted in punctuate nuclear
staining in the majority of cells using ACIF with no staining
in cells infected with the control -galactosidase-expressing
recombinant adenovirus RAd-gal (Fig. 2A). The levels of
EBNA1 expression achieved using RAdEBNA1 were sim-
ilar to those observed in an EBV-transformed lymphoblas-
toid cell line (data not shown; Fig. 4). SVK cells infected
with RAdEBNA1 for 96 h displayed reduced cell numbers
compared to RAd-gal-infected controls and morphological
changes indicative of cytotoxicity such as increased cyto-
plasmic vacuolation were observed (Fig. 2B). No such ef-
fects were seen with RAdEBNA1 infection of HeLa cells or
when RAd-gal (Fig. 2B) or another control RAd express-
ing the influenza nuclear protein (RAdNP) was used to
infect SVK cells (data not shown). The toxic effect of
RAdEBNA1 infection was further examined in different
epithelial cell lines using the MTT assay as a measure of
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cell viability. In both HeLa cells and another epithelial cell
line derived from glandular epithelium, Ad/AH, infection
with a m.o.i.of 100 RAdEBNA1 had little effect on cell
viability (Fig. 3A). However, inhibition of cell viability was
observed upon RAdEBNA1 infection of both SCC12F cells
and SVK cells (Fig. 3A). Infection with a m.o.i. of 30 and
100 of RAdEBNA1 produced significant toxicity in
SCC12F and SVK cells although infection of these cell lines
with the same doses of RAd-gal or a recombinant adeno-
virus expressing influenza nuclear protein (RAdNP) had no
significant toxic effect (data not shown). To ensure that the
observed differential effects of RAdEBNA1 on the viability
of SCC12F and SVK cells versus HeLa and Ad/AH cells
was not due to differences in susceptibility to adenovi-
rus infection, we examined adenovirus infectivity in the
epithelial cell panel using low doses of a reporter virus
expressing GFP (RAdGFP). SVK, Ad/AH, and HeLa cells
were efficiently infected by low doses of RAdGFP com-
pared to SCC12F cells (Fig. 3B). However, at high virus
doses the SCC12F cell line was infected at levels equivalent
Fig. 1. Differential sensitivity of epithelial cell lines to stable EBNA1 expression. Cells were transfected with either a control plasmid [pZIP-SV(X)-neo (neo)]
or an EBNA1-expressing plasmid [pZIP-SV(X)-neo-EBNA1 (EBNA1)]. The cells were electroporated and plated out at 2 105 cells per dish in the presence
of a 3T3 feeder layer. Drug-resistant clones were selected after 4 weeks in the presence of G418. After fixation in 3.7% formal saline dishes were stained
with rhodanile blue, and the number of G418-resistant clones was scored. (A) Representative plates displaying differences in colony formation; (B) data
pooled from three dishes with mean and SE values.
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to those of the other epithelial cell lines (Fig. 2–5: data not
shown).
The effect of EBNA1 expression on the cell cycle profile
of the epithelial cell lines was examined using RAdEBNA1-
and RAd-gal-infected cells. At 96 h postinfection cells
were harvested for FACS analysis and the resultant profiles
are presented in Fig. 3C. The control RAd-gal-infected
profiles (left-hand panels) were identical to those obtained
for uninfected cells and highlighted differences between
Ad/AH and HeLa cells as compared to SCC12F and SVK
cells. Thus Ad/AH and HeLa cells were found to be similar
with a small G2/M peak in contrast to both SCC12F and
SVK cells, which had a larger number of cells in G2/M.
This reflects the more rapid cell cycling time of Ad/AH and
HeLa which grow faster than SCC12F and SVK cells.
RAdEBNA1 infection of Ad/AH and HeLa cells had no
overt effect on the cell cycle, whereas infection of SCC12F
and SVK cells resulted in a significant increase in the G2/M
peak consistent with induction of growth inhibition in these
cells (Fig. 3C).
Fig. 2. Transient expression of EBNA1 induces epithelial cell-type specific cytotoxicity. Actively growing cells were infected with either RAdEBNA1 or
control RAd-gal. Cells were infected at a m.o.i. of 100 PFU/cell. (A) Immunofluoresence staining for EBNA1 expression in SVK and HeLa lines infected
with either RAd-gal or RAdEBNA1 (magnification  400). (B) Phase-contrast photomicrograph of RAd-infected SVK and HeLa cells depicting cell
morphology 96 h postinfection (magnification  100).
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EBNA1 is degraded in epithelial cell lines of squamous
origin and this effect is partially blocked by bcl-2 or
BHRF1 expression
The expression of EBNA1 in RAdEBNA1-infected epi-
thelial cells was examined using immunoblotting with a
specific monoclonal antibody (mAb), 1H4. The various ep-
ithelial cell lines were infected at a m.o.i. of 100 with either
RAdEBNA1 or the control RAd-gal and harvested 96 h
post-infection. Loading equivalent amounts of protein ex-
tract (100 g) revealed that infection with a m.o.i. of 100 of
RAdEBNA1 resulted in similar levels of EBNA1 expres-
sion in HeLa and Ad/AH cells as observed in the IB4
LCL-positive control sample (Fig. 4A). Although the HeLa
and Ad/AH cell lines expressed the adenovirus delivered
EBNA1 as a discrete 70-kDa band, both SCC12F cells and
SVK cells exhibited a range of bands consistent with protein
degradation as well as more pronounced expression of the
full-length protein (Fig. 4A). No such effect was observed
when another nuclear protein (influenza NP) was delivered
by adenovirus (RAdNP) to SCC12F or SVK cells and no
degradation of an endogenous nuclear protein (PCNA) was
detected in the presence of EBNA1 breakdown in these cells
(data not shown). Degradation of EBNA1 and associated
toxicity was also observed at lower doses of RAdEBNA1 in
SVK cells but not HeLa and Ad/AH (Fig. 4B and C). For
these experiments the RAdEBNA1 was purified on a cae-
sium chloride gradient and low doses of the virus were used
to ensure that the observed effect was not a consequence of
EBNA1 overexpression. At these lower doses of
RAdEBNA1 degradation of EBNA1 was observed in SVK
cells but not HeLa cells (Fig. 4B) and this effect was again
associated with more pronounced expression of the full-
length EBNA1 protein in SVK cells. Consequent with
EBNA1 degradation, SVK cells displayed toxicity to low
doses of RAdEBNA1 that was not evident in HeLa cells
(Fig. 4C).
To explore the possibility that the toxicity of EBNA1 in
SCC12F and SVK cells might be related to the degradation
of EBNA1, we infected SCC12F cells stably expressing
either the anti-apoptotic bcl-2 protein (SCC12F-bcl2) or its
EBV homolog BHRF1 (SCC12F-BHRF1) with RAdEBNA1
and examined the subsequent effects on cell growth and
EBNA1 degradation (Fig. 5). The growth inhibitory effect
Fig. 3. EBNA1-induced cytotoxicity is associated with a G2/M growth arrest. (A) Cytotoxicity assays of SCC12F, SVK, Ad/AH, and HeLa cells infected
with either RAdEBNA1 or RAd-gal at a m.o.i. of 100. The cells were assayed at 96 h after infection on 96-well plates in triplicate using the MTT assay.
In each case, growth inhibition was calculated by expressing the differences in optical densities between RAdEBNA1-infected cells and control RAd-gal-
infected cells as a percentage of the control. Each assay was performed in triplicate. Results from triplicate determinations were used to calculate the mean
differences and error bars represent standard error of the mean. (B) The epithelial cell panel was infected with low doses of RAdGFP and GFP expression
measured 48 h postinfection using FACS analysis. Data is presented as mean GFP expression. (C) Cell cycle profile analysis was performed on the epithelial
cell panel 96 h after infection with a m.o.i. of 100 of RAd-gal or RAdEBNA1. Fixed cells were stained with propidium iodide, and the relative proportion
of cells in G1, S, and G2/M was determined by multicycle analysis.
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of EBNA1 expression in SCC12F cells was significantly
inhibited by both bcl-2 and BHRF1 (Fig. 5A). However,
bcl-2 expression was more effective at blocking EBNA1
toxicity than BHRF1. To examine the effects of bcl-2 and
BHRF1 on EBNA1 degradation, vector control SCC12F
cells or SCC12F cells expressing bcl-2 or BHRF1 were
infected with a m.o.i. of 100 of RAdEBNA1 and harvested
for immunoblotting at 24, 48 72, and 96 h postinfection.
Expression of either bcl-2 or BHRF1 significantly dimin-
ished but did not completely block the degradation of
EBNA1 in SCC12F cells (Fig. 5B). Thus, at 48 h postin-
fection substantial degradation of EBNA1 is observed in
SCC12Fneo cells compared with the same time point in
SCC12F cells expressing either bcl-2 or BHRF1 (Fig. 5B).
These data implicate EBNA1 degradation in the cytotoxic-
ity observed in response to EBNA1 expression in SCC12F
and SVK cells and suggest that the altered cellular environ-
ment induced by bcl-2 or BHRF1 can protect from both of
these effects.
To determine whether the process of EBNA1 degrada-
tion was a nonspecific consequence of cell death induction,
HeLa cells stably expressing EBNA1 were treated with
either cisplatin or the CH11 anti-fas antibody for 24 h and
subsequently examined for cytotoxicity and EBNA1 degra-
dation. Both cisplatin treatment (Fig. 6A) and exposure to
anti-fas antibody (data not shown) resulted in a significant
reduction in cell viability but there was no effect on the
protein levels of EBNA1 or its degradation (Fig. 6B).
CTL recognition of endogenously processed EBNA1
The degradation of EBNA1 in squamous epithelial cells
raised the possibility that, despite the presence GA repeat
domain, the full-length protein may be processed into the
HLA class I pathway for recognition by EBNA1-specific
CTLs in these cells. In a previous study we demonstrated
HLA-B35.01 restricted CTL responses to EBNA1 and iden-
tified an 11-mer peptide between residues 407 and 417
(HPVGEADYFEY) as a major target epitope in the context
of B35.01 (Blake et al., 1997). To investigate the ability of
CTL to recognize EBNA1 in epithelial cells, a B35.01
transfectant of SVK cells was generated (SVK-B35) and
infected for different lengths of time with a m.o.i. of 100 of
either RAdEBNA1 or control RAd-gal. EBNA1-specific
B35.01-restricted CD8 CTL clones were then used in
cytotoxicity assays targeted against the various RAd-in-
fected SVK-B35 cells. At 48 h postinfection, consistent but
low-level recognition of RAdEBNA1-infected SVK-B35
Fig. 4. EBNA1 is degraded in an epithelial cell type-specific manner. (A) Ad/AH, HeLa, SCC12F, and SVK cell lines were infected with RAd-gal or
RAdEBNA1 at a m.o.i. of 100 and total cell extracts made 96 h postinfection. Equivalent amounts of protein extract (100 g) were immunoblotted for EBNA1
using the 1H4 mAb. IB4 LCL cells were included as a positive control. (B) HeLa and SVK cell lines were infected with low doses of RAdEBNA1 and then
harvested and analyzed with immunoblotting as described above. (C) The effect of low doses of RAdEBNA1 on the viability of HeLa and SVK cells was
determined in triplicate using the MTT assay. The data, representative of at least three independent assays, is expressed as percentage cell viability and the
values presented are the means of triplicate determinations. Standard errors were less than 10% at each point and have not been shown.
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cells was evident (Fig. 7A). At 96 h postinfection, when
both cytotoxicity and EBNA1 degradation are maximal,
strong lysis of RAdEBNA1-infected SVK-B35 cells equiv-
alent to that obtained with SVK-B35 cells pulsed with the
B35-restricted 407–417 EBNA1 peptide was observed (Fig.
7A). These data were reproducible using six different CTL
clones. Given our previous work demonstrating that full-
length EBNA1 can be exogenously processed and presented
on HLA class I molecules by a TAP-independent pathway
(Blake et al., 1997), we examined whether the recognition
of EBNA1 in SVK-B35 cells is due to the exogenous uptake
of EBNA1 liberated from dead cells. Overnight incubation
of SVK-B35 cells with full-length EBNA1 protein resulted
in only minimal recognition by EBNA1-specific CTL
clones (Fig. 7B). Finally, to determine whether EBNA1
expression in HeLa cells results in CTL recognition we used
HeLa cells stably expressing EBNA1 (HeLa-EBNA1) and
rendered B35.01 positive by infection with a recombinant
vaccinia virus (vB35). No recognition of B35.01-positive
HeLa-EBNA1 cells was found even after treatment with
interferon-, although incubation of vB35-infected cells
with the 407–417 peptide resulted in significant lysis (Fig.
7C). This effect is not due to a fundamental defect in the
ability of HeLa cells to process and present antigen as
GA-deleted EBNA1 delivered by a recombinant vaccinia
virus (vE1GA) to interferon- treated HeLa cells was
efficiently recognized in the context of B35.01 by specific
CTL clones (Fig. 7D).
The ability to sustain long-term EBV infection is
epithelial cell-type specific
Given the key role of EBNA1 in the maintenance of
EBV infection, it is likely that the toxic effect of EBNA1 in
SVK and SCC12F cells will prevent the establishment of
stable EBV infection, whereas those epithelial cell environ-
ments in which EBNA1 is not toxic (e.g., HeLa and Ad/AH)
will be capable of sustaining virus infection. To investigate
this possibility, we engineered an adenovirus expressing the
B-cell receptor for EBV (RAd-CR2) and used this to effi-
ciently deliver a neomycin-resistant recombinant EBV
(rEBV) to HeLa cells and SVK cells. Forty-eight hours after
infection with RAd-CR2, the cell lines were incubated with
rEBV and the initial efficiency of EBV infection, as deter-
mined by EBER in situ hybridization, was found to be
between 20 and 25% at 5 days postinfection in both HeLa
and SVK cells. However, subsequent selection in G418 for
3–4 weeks resulted in the isolation of numerous EBV-
positive clones in HeLa cells but not SVK cells (Fig. 8),
consistent with the behavior of EBNA1 in these different
cell backgrounds.
Discussion
The expression of EBNA1 in all forms of EBV latent
infection is consistent with the central role of this nuclear
protein in the maintenance and segregation of the EBV
Fig. 5. EBNA1-induced effects in the SCC12F cell background are inhibited by bcl-2 and BHRF1 expression. (A) SCC12F cells, SCC12F-bcl-2 cells, or
SCC12F-BHRF1 cells were infected with either RAd-gal or RAdEBNA1 at a m.o.i. of 100. Cell viability was assayed at 96 h postinfection using the MTT
assay. In each case, growth inhibition was calculated by expressing the differences in optical densities between RAdEBNA1-infected cells and control
RAd-gal-infected cells as a percentage of the control. Each assay was performed in triplicate. Results from triplicate determinations were used to calculate
the mean differences and error bars represent standard error of the mean. (B) Cell lysates from SCC12F cells, SCC12F-bcl-2 cells, and SCC12F-BHRF1 cells
were immunoblotted for EBNA1 expression (upper panel) using the 1H4 mAb of cell extracts taken 96 h postinfection with a m.o.i. of 100 of RAdEBNA1
or RAdNP as a negative control (lane C). Immunoblotting for PCNA (lower panel) was used as a loading control.
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episome. This function of EBNA1 has been extensively
studied in B cells, where in vitro infection with EBV is
efficient and results in B-cell transformation. The situation
with regard to epithelial EBV infection is less clear. Al-
though EBV infection of epithelial cells obviously occurs in
the context of virus-associated carcinomas, the require-
ments for this process are poorly defined. Our previous
work suggested that stable infection of epithelial cells re-
quires an undifferentiated epithelial cell environment and
this is supported by the current study that indicates that
EBNA1 expression is only tolerated in epithelial cells of
either glandular (adenocarcinoma) origin or undifferentiated
squamous cells (Knox et al., 1996). This observation is
consistent with earlier reports in which stable EBNA1 ex-
pression could be achieved either by transfection of EBNA1
into undifferentiated cell lines derived from adenocarcino-
mas such as HeLa or by somatic cell hybridization of BL
cell lines or fresh NPC cells with HeLa or the Ad/AH line,
another undifferentiated adenocarcinoma cell line (Glaser et
al., 1972; Takimoto et al., 1985; Vidal et al., 1990). Thus, an
important corollary of this work is that a prerequisite for
persistent EBV infection of epithelial cells is a cellular
environment in which EBNA1 expression can be main-
tained. This also explains the efficiency with which epithe-
lial cell lines of adenocarcinoma origin could be infected
and selected with a recombinant neomycin-tagged EBV
compared to cell lines derived from squamous carcinomas
(Imai et al., 1998; Jones, Young, and Dawson, unpublished
observations). Introduction of bcl-2 into the SCC12F cell
line results in an undifferentiated cell environment similar
to that of either normal basal epithelial cells or NPC cells,
both of which are bcl-2 positive, and this permits tolerance
of EBNA1 expression (Dawson et al., 1998). This effect is
unlikely to be a direct consequence of the antiapoptotic
function of bcl-2 on EBNA1-induced cytotoxicity but rather
the more global effect of bcl-2 on the epithelial cell pheno-
type. Thus, it is possible that persistent infection of squa-
mous epithelium in vivo could result from entry of EBV
into either basal keratinocytes or more differentiated epithe-
lial cells that have undergone premalignant changes result-
ing in a survival advantage (i.e., deregulated bcl-2 expres-
sion and p53 mutation). The ability of the BHRF1
immediate early protein of EBV, a viral homologue of
bcl-2, to protect against the toxicity of EBNA1 and to block
epithelial differentiation may be relevant to its proposed
role in prolonging the life span of lytically infected cells to
ensure the efficient replication and dissemination of infec-
tious virus (Dawson et al., 1995, 1998). We have previously
demonstrated EBNA1 expression in the epithelial cells sup-
porting EBV lytic infection in oral hairy leukoplakia (HL)
and speculated that EBNA1 may be required to maintain the
EBV episome during the “rolling circle” replication process
characteristic of herpesviruses (Murray et al. 1996). Thus,
an additional consequence of the altered epithelial cell en-
Fig. 6. Induction of apoptosis in stable HeLa-EBNA1 cells is not associated with EBNA1 degradation. (A) HeLa-EBNA1 cells were susceptible to
cisplatin-induced cell death as determined in triplicate using the MTT assay. The data, representative of at least three independent assays, are expressed as
a percentage of cell viability relative to untreated cells and the values presented are the means of triplicate determinations. Standard errors were less than
10% at each point and have not been shown. (B) HeLa-EBNA1 cells were treated with 5  104 M cisplatin for 24 h and protein extracts immunoblotted
for EBNA1 expression using the 1H4 mAb.
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vironment induced by BHRF1 is the stable expression of
EBNA1 in the differentiating squamous epithelium of HL.
EBNA1 expression in squamous epithelial cell lines re-
sulted in cytotoxicity associated with a G2/M growth arrest.
This effect correlated with EBNA1 degradation temporally
and the interrelatedness of the cytotoxicity with EBNA1
degradation was confirmed by their mutual reduction in
response to bcl-2 or BHRF1 expression. This suggests that
the cytotoxic and degradation processes are related but the
mechanisms responsible for these effects remain unknown.
It is possible that the degradation of EBNA1 liberates pro-
tein fragments that interfere with the transcription or func-
tion of cell cycle-related genes and thus further investiga-
tion of cyclin, cyclin-dependent kinases, and cdk inhibitors
is warranted. In this regard it is intriguing that the processes
of cell cycle progression and apoptosis are intimately asso-
ciated with tightly regulated protein degradation and the
possibility that EBNA1 breakdown is linked to these effects
is currently under investigation (Hershko and Chiech-
anover, 1998). However, the inability to induce EBNA1
degradation in stable HeLa-EBNA1 transfectants induced
into apoptosis by either anti-fas antibody or cisplatin sug-
gests that EBNA1 degradation is not an inevitable conse-
quence of apoptosis. Likewise, we have only been able to
detect low levels of apoptosis in response to EBNA1 ex-
pression in SVK and SCC12F cells (data not shown) con-
firming that the toxicity of EBNA1 in these cells is predom-
inantly associated with growth arrest rather than cell death.
Fig. 7. Processing and presentation of EBNA1 for MHC Class I CTL recognition in SVK but not HeLa cells. (A) SVK-B35 cells were infected with RAd-gal
or RAdEBNA1 and used in standard chromium release assays (CRAs) at 48 and 96 h postinfection; as controls, target cells were preexposed to the EBNA1
407–417 epitope peptide. HLA B*3501-restricted CTL clones (EM c2 and c4) specific for the EBNA1 407–417 epitope were used at an effector-to-target
(E:T) ratio of 6:1 and 3:1 as indicated. (B) SVK-B35 cells preexposed to either EBNA1 protein (bEBNA1) or control human papillomavirus E4 protein (bE4),
both expressed from baculovirus vectors, were used in a CRA with HLA B*3501-restricted CTL from EM c2 at the indicated E:T ratios (5:1 and 2:1). Target
cells were exposed to protein at 5 g/ml for 14 h at 37°C before being used in the CRA. Targets were also treated with EBNA1 407–417 epitope peptide
or DMSO solvent control as in (A). (C) Stable HeLa-EBNA1 transfectants, either untreated or treated with IFN (1000 U/ml for 48 h), were infected with
a control vaccinia (vTK-) or a vaccinia expressing the HLA B*3501 heavy chain alone (vB35); as a control untreated cells were infected with vB35 and
exposed to either the EBNA1 407–417 epitope peptide or DMSO solvent control. HLA B*3501-restricted CTL clone EM c106 specific for the EBNA1
407–417 epitope was used at an E:T of 4:1 and 2:1. (D) HeLa cells, either untreated or treated with IFN (1000 U/ml) for 48 h), were infected with a vaccinia
expressing EBNA1 deleted for the GAr domain (vE1GA), vB35 or co-infected with vE1GA and vB35; as a control untreated cells were infected with vB35
and exposed to either the EBNA1 407–417 epitope peptide or DMSO solvent control. HLA B*3501-restricted CTL clone EM c110 specific for EBNA1
407–417 epitope was used at the indicated E:T ratios.
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The mechanism responsible for EBNA1 degradation re-
mains unknown although more detailed analysis is war-
ranted particularly to explore the possibility that EBNA1 is
ubiquitinated in the SVK and SCC12F cell lines but not in
the nondegradative HeLa and Ad/AH cell lines. Another
intriguing observation is that the degradation of EBNA1 in
SCC12F and SVK cells is associated with the overexpres-
sion of the full-length protein. This effect may be a conse-
quence of the associated toxicity of EBNA1 in these epi-
thelial cells that results in the accumulation of the protein
rather than the partitioning of the stable protein during cell
division in cells where EBNA1 is not toxic. This possibility
is currently under investigation.
Whatever the mechanisms responsible for EBNA1-in-
duced cytotoxicity and degradation, these effects appear to
be manifest in immortalised (SCC12F, SVK) rather than
fully transformed (HeLa, Ad/AH) cellular environments
implying that mutations associated with transformation may
contribute to the maintenance of EBNA1 expression and
thereby facilitate persistent EBV infection. These data also
suggest that in certain epithelial cell environments EBNA1
may activate cytotoxic pathways extending the function of
Fig. 8. The ability to sustain stable infection with EBV is epithelial cell-type specific. HeLa and SVK cells were infected with RAd-CR2 followed by infection
with a neomycin-resistant recombinant EBV. The initial efficiency of EBV infection as determined by EBER in situ hybridization was between 20 and 25%
at 5 days postinfection in both HeLa and SVK cells. Drug resistant clones were selected after 4 weeks in the presence of G418. After fixation in 3.7% formal
saline dishes were stained with rhodanile blue, and the number of G418 resistant clones were scored. (A) Representative plates displaying differences in
colony formation; (B) data pooled from four independent experiments with mean and SE values.
672 R.J. Jones et al. / Virology 313 (2003) 663–676
this protein beyond its role in EBV episomal maintenance
and segregation. Consistent with this is the possible role of
EBNA1 in transformation suggested by the development of
undifferentiated B-cell lymphomas in EBNA1 transgenic
mice (Wilson et al., 1996). The ability of the HHV-8-
encoded EBNA1 equivalent LANA to influence p53 and
pRB function and of the HPV31-encoded E6 and E7 onco-
proteins to promote episomal stability highlights overlap-
ping transforming and viral genome maintenance functions
that may be relevant to EBNA1 (Friborg et al., 1999; Radov
et al., 2000; Thomas et al., 1999).
The degradation of EBNA1 in epithelial cells was asso-
ciated with the processing and presentation of this protein to
specific CTLs. This result is surprising given the reported
role of the GA repeats in inhibiting ubiquitin/proteasome-
dependent protein degradation but these previous studies
were performed either in B cells or fibroblasts (Levitskaya
et al., 1995, 1997). The current data demonstrates that the
processing of EBNA1 is cell type dependent and raises the
possibility of lineage-associated diversity in the pathways
responsible for antigen processing. The role of epithelial
cells in the natural history of EBV infection is controversial
with recent work implicating B cells as the seat of EBV
persistence (Babcock et al., 1998; Young, 1999). In this
scenario the infection of epithelial cells by EBV is consid-
ered to be an accidental event resulting from the local
reactivation of latently infected B cells. A consequence of
epithelial infection is then either differentiation-dependent
EBV replication as evidenced by HL or latent infection that
has the potential to contribute to carcinogenesis (Greenspan
et al., 1985; Pathmanathan et al., 1995). Thus, the behavior
of EBNA1 in epithelial cells as demonstrated in the current
study may be critical to the outcome of epithelial infection.
EBNA1 is expressed during EBV lytic infection in epithe-
lium and these cells could be recognized and eradicated by
EBNA1-specific CTLs (Murray et al., 1996). In this context
it is interesting that strong CTL responses to EBNA1 and to
EBV lytic antigens are frequently detected in both primary
and persistent infection and these responses may be sus-
tained by the continual reinfection of epithelial cells by
EBV (Blake et al., 2000; Steven et al., 1997). This effect
could also account for the difficulties in routinely detecting
EBV infection in normal epithelium. Another consequence
of our findings is that persistent EBV infection of epithe-
lium would require an epithelial cell environment in which
EBNA1 is not toxic and is thereby protected from CTL
recognition. This contention is supported by our data dem-
onstrating that stable EBV infection can be achieved in
HeLa cells where EBNA1 expression results in no growth
inhibition and is not recognized by EBNA1-specific CTLs,
whereas, in agreement with our previous studies (Li et al.,
1992), stable EBV infection cannot be sustained in the SVK
cell background in which EBNA1 is toxic and is processed.
Taken together the current study identifies a previously
unrecognized property of EBNA1 in inducing cytotoxicity
in epithelial cells related to protein degradation and endog-
enous processing. An understanding of the mechanisms
underlying these effects is relevant to the biology of EBV in
normal infection as well as the role of EBV in the carcino-
genic process and may help in the development of thera-
peutic approaches to virus-associated malignancies.
Materials and methods
Cell culture
The SCC12F cell line was cultured in DMEM/F-12 (3:1)
supplemented with 5% fetal calf serum (GIBCO), 2 mM
glutamine, hydrocortisone (0.4 g/ml) (Upjohn), and the
antibiotics penicillin (1000 U/ml) and streptomycin (1 mg/
ml) (Sigma). The cell lines SCC12F-bcl2/12 and SCC12F-
BHRF1/6 (Dawson et al., 1995) are derivatives of the
SCC12F cell line stably transfected with either bcl2 or
BHRF1 and expression is maintained under selection with
G418 (400 g/ml). For routine cell culture SCC12F cells
were grown at clonal density on an irradiated 3T3 fibroblast
feeder layer (Parkinson et al., 1983). Both the HeLa and
Ad/AH cell lines were cultured in DMEM with 5% fetal calf
serum (GIBCO), 2 mM glutamine, and the antibiotics pen-
icillin (1000 U/ml) and streptomycin (1 mg/ml) (Sigma).
SVK cells (a SV40-immortalized human keratinocyte cell
line) was cultured in Jocklics supplemented with 5% fetal
calf serum (Gibco), 2 mM glutamine, hydrocortisone (0.4
g/ml), and the antibiotics penicillin (1000 U/ml) and strep-
tomycin (1 mg/ml). For induction of apoptosis in stable
HeLa-EBNA1 clones, actively growing cells were plated at
density of 2  106 cells per dish and allowed to grow
overnight before treatment with either 5  104M cisplatin
or 50 ng/ml CH11 anti-Fas monoclonal antibody (Immuno-
tech) and 10 g/ml cycloheximide for 24 h.
Generation of epithelial cell lines with stable EBNA1
expression
Stable clones of SCC12F- or HeLa-expressing EBNA1
were generated by electroporation as described previously
(Dawson et al., 1990). Briefly, 2  106 actively growing
cells were electroporated with either pZIPSV(X)1-neo or
the EBNA1 expression vector pZIPSV(X)1-neo-EBNA1.
After electroporation, 2  105 cells were plated in triplicate
onto 5-cm petri dishes in complete growth medium. For
SCC12F cells, cells were seeded onto dishes containing
-irradiated 3T3 feeder cells. The generation of stable,
drug-resistant clones was monitored after 3 weeks of selec-
tion in medium containing 400 g/ml G418. After this time,
the dishes were washed twice with phosphate-buffered sa-
line (PBS), fixed in 3.7% formal saline, and stained with
rhodanile blue. The number of drug resistant colonies was
then scored.
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Adenovirus infections
Adenoviral constructs RAd-gal (containing -galacto-
sidase), RAdNP (containing influenza nuclear protein), or
RAdEBNA1 (containing EBV-encoded EBNA1) were all
kindly provided by Dr. G. Wilkinson (University College of
Medicine, Cardiff, Wales, United Kingdom). RAdGFP was
generated in house 24 h after plating, and the epithelial cell
lines were incubated with RAd virus for 2 h at 37°C at
different multiplicities of infection. In some experiments
RAdEBNA1 was purified on cesium chloride gradients us-
ing standard techniques. Infections were all carried out in
DMEM supplemented with 2% fetal calf serum (Gibco).
After infection, the cell cultures were transferred to com-
plete growth medium. All cells were harvested 96 h postin-
fection unless otherwise stated.
Analysis of EBNA1 expression
EBNA1 expression was examined using anti-comple-
ment immunofluorescence (ACIF) and immunoblotting.
ACIF staining was performed on cell smears fixed at20°C
in methanol:acetone (1:1) for 10 min. Following rehydra-
tion in EBNA wash buffer (PBS/0.1% CaCl2, 0.1% MgCl2,
w/v), the smears were incubated with 1:100 dilution of a
monospecific human serum (Mo) or an EBV-negative se-
rum (PR). The smears were subsequently washed and incu-
bated with guinea pig complement (1:10, ICN) followed by
FITC-conjugated antiguinea pig C3 monoclonal antibody
(1:100, ICN). The slides were then washed and mounted in
an antifading agent prior to visualisation under an Olympus
UV-fluorescence microscope. Standard immunoblotting
techniques were also used to examine EBNA1 expression.
Briefly the cell lines were harvested 96 h postinfection,
harvested in 20 l of urea buffer (9M urea in Tris, pH 7.0),
sonicated, and diluted in gel sample. One hundred micro-
grams of each extract was separated on a 7.5% SDS–PAGE
gel. Separated proteins were blotted onto nitrocellulose
membrane and, after blocking for 2 h with PBS–Tween
(0.1%) containing 5% fat-free skimmed milk, incubated
overnight at 4°C with 1H4 (1:50), a rat monoclonal anti-
body specific for EBNA1 (Murray et al., 1996). After two
15-min washes in PBS–Tween (0.1%) the nitrocellulose
membrane was incubated for 90 min with HRP-conjugated
goat antirat immunoglobulin (1:12,000) (Sigma). After an
additional two 60-min washes in PBS–Tween (0.1%), anti-
body–protein complexes were visualized with ECL chemi-
luminesence (Amersham).
Cell viability analysis
Actively growing cells were infected with RAd-gal and
RAdEBNA1 at an m.o.i. of 100 or lower and refed with
normal growth medium. At 72 h postinfection the cells were
plated in triplicate at 104 cells per well in 96-well plates
(Nunc) and allowed to grow overnight before the MTT
assay was carried out. Briefly, 20 l of a 5 mg/ml stock of
MTT (3-[4,4 dimethylthiazol-2-yl]-2, 5-diphenyl tetrazo-
lium bromide, Sigma) in PBS was added to each well, and
the cells were incubated with substrate for 5 h. After the
incubation, spent medium was aspirated from the wells and
the formazan crystals solubilized in 200 l of DMSO
(Fisons). The absorbance was then determined at 550 nm on
a Becton–Dickinson Multiscan. In each case, growth inhi-
bition was calculated by expressing the differences in opti-
cal densities between RAdEBNA1-infected cells and con-
trol RAd-gal infected cells as a percentage of the control.
Each assay was performed in triplicate. Results from trip-
licate determinations were used to calculate the mean dif-
ferences and error bars represent standard error of the mean.
Cell cycle analysis
All cell types were harvested by trypsinization 96 h
postinfection, fixed in 70% ethanol, and then stored at
20°C until analysis. Cells were then pelleted by centrifu-
gation (800g) and rehydrated in 500 l PBS. The cells were
then processed for DNA analysis on a Coulter DNA prep
workstation. Twenty microliters of propidium iodide was
added (50 g/ml), and the cells were analyzed with flow
cytometry on an EPICS XL (Coulter) (488-nm excitation,
620-nm emmision). Cell cycle profiles were calculated with
the Multicycle software package (version 2.53) (Phoenix
Software, San Diego, CA, USA).
CTL clones and chromium release assays
EBV EBNA1-specific CTL clones restricted through
HLA B*3501 (EBNA1 minimal epitope HPVGEADYFEY;
aa 407–417) were generated and maintained as described
previously (Blake et al., 1997). SVK-B35 cells were in-
fected with RAds at a m.o.i. of 100 for either 48 or 96 h
before being labeled with 75 Ci of (51Cr)O4 for 90 min,
washed, and incubated with CTL at known effector-to-
target (E:T) ratios in a standard 5-h chromium release assay.
Where vaccinia viruses were used to express either EBNA1
or the HLA B*3501 molecule, target cells were infected at
an m.o.i. of 10 for 90 min, followed by incubation for 15 h
prior to use as targets in chromium release assays. For
assays involving protein loading, target cells were incubated
overnight at 37°C with protein (5 g/ml) before labeling.
Where peptide was used, target cells were incubated with
peptide at a concentration of 2  108 M or DMSO solvent
alone. The percentage of specific lysis was calculated as
(release by CTL  spontaneous release)  100/(total re-
lease in 1% SDS  spontaneous release). Spontaneous
release of target cells was 25% in all assays.
Selection of EBV-infected epithelial cell lines
SVK or HeLa cells were plated out at a density of 2 
106 cells/dish and were infected 24 h later with a m.o.i. of
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100 of a recombinant adenovirus expressing CR2 (RAd-
CR2). The cells were then cocultured with induced Akata-
neo cells which produce recombinant Akata strain EBV
(rEBV) carrying the neomycin selectable marker in the
BDLF3 gene (Borza and Hutt-Fletcher, 1998). After 4 days,
the cultures were washed and G418 selection applied for
3–4 weeks. After this time, the dishes were washed twice
with PBS, fixed in 3.7% formal saline, and stained with
rhodanile blue. The number of drug-resistant colonies was
then scored.
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